A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer

“Tumor biology is king; selection is queen; and technical maneuvers are the princes and princesses trying to usurp the throne, sometimes with temporary apparent victories, and usually to no long-term avail.” Perhaps no other disease lends itself to the fundamental tenets of surgical oncology—eloquently outlined by Blake Cady over 20 years ago—as pancreatic ductal adenocarcinoma (PDAC).1 Fortunately, multimodality therapies for the treatment of...